Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease - A quantitative analysis

Department of Statistics, Stanford University, Palo Alto, California, United States
Chest (Impact Factor: 7.48). 11/2005; 128(4):2327-35. DOI: 10.1378/chest.128.4.2327
Source: PubMed


To evaluate quantitative air trapping measurements in children with mild cystic fibrosis (CF) lung disease during a 1-year, double-blind, placebo-controlled, recombinant human deoxyribonuclease (rhDNase) [dornase alfa] intervention trial and compare results from quantitative air trapping with those from spirometry or visually scored high-resolution CT (HRCT) scans of the chest.
Twenty-five children with CF randomized to either daily rhDNase or placebo aerosol were evaluated at baseline, and at 3 months and 12 months by spirometer-triggered HRCT and spirometry. Outcome variables were percentage of predicted FVC, FEV1, and forced expiratory flow, midexpiratory phase (FEF(25-75%)); total and subcomponent visual HRCT scores; and quantitative air trapping measurements derived from chest HRCT images.
At baseline, there were no statistical differences between groups in any of the variables used as an outcome. After 3 months of treatment, both groups had improvements in percentage of predicted FEV1 and FEF(25-75%), and total HRCT visual scores. In contrast, the rhDNase group had a 13% decrease in quantitative air trapping from baseline (severe air trapping [A3]), compared to an increase of 48% in the placebo group (p = 0.023). After 12 months, both groups had declines in percentage of predicted FVC and FEV1, but the rhDNase group retained improvements in percentage of predicted FEF(25-75%) and quantitative air trapping. The mucus plugging and total HRCT visual scores were also improved in the rhDNase group after 12 months of treatment, with and without significant differences between groups (p = 0.026 and p = 0.676). Quantitative air trapping (A3) remained improved in the rhDNase group (- 15.4%) and worsened in the placebo group (+61.3%) with nearly significant differences noted between groups (p = 0.053) after 12 months of treatment.
Quantitative air trapping is a more consistent sensitive outcome measure than either spirometry or total HRCT scores, and can discriminate differences in treatment effects in children with minimal CF lung disease.

Download full-text


Available from: Richard B Moss
  • Source
    • "Well-described factors that increase TGF-β signal transduction in cystic fibrosis airways include local hypoxia [28], [29], persistent epithelial injury, and increased protease activity [30]–[32]. Furthermore, myofibroblasts themselves promote TGF-β activation via contraction [33], and mechanical strain in CF is pronounced due to mucus plugging [34], heterogeneous air trapping [35], and chronic cough. The environment in the CF lung is therefore well primed for increased TGF-β signaling, myofibroblast differentiation and persistence of pathologic fibroblast behavior as established here. "
    [Show abstract] [Hide abstract]
    ABSTRACT: TGF-β, a mediator of pulmonary fibrosis, is a genetic modifier of CF respiratory deterioration. The mechanistic relationship between TGF-β signaling and CF lung disease has not been determined. To investigate myofibroblast differentiation in CF lung tissue as a novel pathway by which TGF-β signaling may contribute to pulmonary decline, airway remodeling and tissue fibrosis. Lung samples from CF and non-CF subjects were analyzed morphometrically for total TGF-β1, TGF-β signaling (Smad2 phosphorylation), myofibroblast differentiation (α-smooth muscle actin), and collagen deposition (Masson trichrome stain). TGF-β signaling and fibrosis are markedly increased in CF (p<0.01), and the presence of myofibroblasts is four-fold higher in CF vs. normal lung tissue (p<0.005). In lung tissue with prominent TGF-β signaling, both myofibroblast differentiation and tissue fibrosis are significantly augmented (p<0.005). These studies establish for the first time that a pathogenic mechanism described previously in pulmonary fibrosis is also prominent in cystic fibrosis lung disease. The presence of TGF-β dependent signaling in areas of prominent myofibroblast proliferation and fibrosis in CF suggests that strategies under development for other pro-fibrotic lung conditions may also be evaluated for use in CF.
    Full-text · Article · Aug 2013 · PLoS ONE
  • Source
    • "Recombinant human DNase (dornase alfa) has been developed to cleave high molecular weight DNA released by dead neutrophils that contributes to the tenacity of airway phlegm [92]. Daily inhalation of aerosolized dornase alfa can reverse early air trapping [93] and ventilation inhomogeneity [94]; decrease sputum markers of local inflammation [92,95]; reduce pulmonary exacerbation risk [33,35]; improve CF pulmonary function [33,35]; slow the rate of at which pulmonary function is lost [96]; and improve survival [97]. It is generally well-tolerated and has become a mainstay in the recommended treatments to maintain lung health [98]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the discovery of the gene associated with cystic fibrosis (CF), there has been tremendous progress in the care of patients with this disease. New therapies have entered the market and are part of the standard treatment of patients with CF, and have been associated with marked improvement in survival. Now there are even more promising therapies directed at different components of the pathophysiology of this disease. In this review, our current knowledge of the pathophysiology of lung disease in patients with CF is described, along with the current treatment of CF lung disease, and the therapies in development that offer great promise to our patients.
    Full-text · Article · Aug 2012 · BMC Medicine
  • Source
    • "In addition, Brody et al147 showed that there was correlation between the frequency of pulmonary exacerbations and CT score. Small intervention studies in patients with CF have demonstrated improvement in overall CT score following treatment.148,149 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cystic fibrosis (CF) is the most common life-shortening genetic disorder in Caucasians. With improved diagnosis and treatment, survival has steadily increased. Unfortunately, the overwhelming majority of patients still die from respiratory failure caused by structural damage resulting from airway obstruction, recurrent infection, and inflammation. Here, we discuss the role of inflammation and the development of anti-inflammatory therapies to treat CF lung disease. The inflammatory host response is the least addressed component of CF airway disease at this time. Current challenges in both preclinical and clinical investigation make the identification of suitable anti-inflammatory drugs more difficult. Despite this, many researchers are making significant progress toward this goal and the CF research community has reason to believe that new therapies will emerge from these efforts.
    Full-text · Article · Aug 2010 · Journal of Inflammation Research
Show more